Market Overview

Geron Data from Myelofibrosis IST to be Presented at ASH Oral Session on December 9 -8K


In November 2012, Dr. Ayalew Tefferi at Mayo Clinic initiated an investigator-sponsored trial to evaluate the safety and efficacy of imetelstat in patients with myelofibrosis, and to determine an appropriate dose and schedule for further evaluation (the "Myelofibrosis IST").

Geron Corporation (NASDAQ: GERN) has been informed by Dr. Tefferi that his abstract on preliminary data from the ongoing Myelofibrosis IST has been selected by the American Society of Hematology (ASH) Program Committee for presentation in an Oral Session at the 55th ASH Annual Meeting and Exposition in New Orleans, LA. The presentation is scheduled to occur during the Myeloproliferative Syndromes: Clinical: Novel Therapeutic Strategies session on Monday, December 9, 2013 at 4:45 p.m. local time.

Posted-In: News Guidance FDA Management Events


Related Articles (GERN)

View Comments and Join the Discussion!

Market Primer: Tuesday, October 15: Tuesday Could Be 'Deal Day'

WiLAN, Novatel Wireless Enters into License and Settlement Agreement with